This phase III trial is evaluating acalabrutinib and rituximab (two anti-cancer drugs), given in combination with idelalisib or bendamustine (chemotherapy), for the treatment of Chronic Lymphocytic Leukaemia (CLL).
This trial is treating patients with Chronic Lymphocytic Leukaemia.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Acerta Pharma BV
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More